11/2/2006 GENEREX BIOTECHNOLOGY SPONSORS EPISODE OF MEDICAL MISSIONS FOR CHILDREN PLAIN TALK ABOUT HEALTH PROGRAM ON AVIAN INFLUENZA
November 2, 2006 –Generex Biotechnology Corporation (NasdaqCM:GNBT) announced today that it has sponsored an episode of the Medical Missions for Children (www.mmissions.org) talk show Plain Talk About Health. The episode, entitled A Discussion about the Global Impact of an Avian Influenza Pandemic, is scheduled to first air on the Medical Broadcasting Channel (MBC) on November 3, 2006. The episode, which will air an aggregate of 18 times on MBC in the month of November, 2006, is co-hosted by Tommy Thompson, United States Secretary of Health & Human Services, and Mary Alice Williams, an award-winning writer, anchor, correspondent, and television host.
Medical Missions for Children (MMC) is dedicated to serving the medical needs of catastrophically ill children in underserved communities around the world. Through the use of its Global Telemedicine & Teaching Network™ (GTTN), a satellite and Internet-based communications platform, MMC facilitates the real-time treatment of remote, critically ill children. The GTTN also broadcasts an extensive program of medical education and supports dialogue exchange among a global network of medical specialists.
Today, Medical Missions for Children’s global network creates a communications bridge between pediatric healthcare facilities in Latin America, Africa, India, the Middle East, Eastern Europe, and Central Asia and a volunteer service corps from 30 tier-one medical institutions based both at home and abroad.
MMC’s Medical Broadcasting Channel (MBC) is a private, not-for-profit television network fully licensed by the US Federal Communications Commission as a global satellite broadcaster. Programming content is delivered directly from MMC’s Global Video Library of Medicine and covers a wide variety of topics including physician education, nursing education, patient education, prevention, family health, and medical science. Programming is transmitted via satellite on Intelsat 903 and multicast on Internet2 and its affiliated research and education networks. MBC currently broadcasts to more than 100 countries.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device. The Company’s flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," “forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
# # #
Contacts:
Shayne Gilliatt
Generex Biotechnology Corporation
Phone: (800) 391-6755
or (416) 364-2551
Andrew Hellman
CEOcast, Inc.
Phone: (212) 732-4300
Dolores Naney
Rubenstein Public Relations
Phone: (212) 843-8018
dnaney@rubensteinpr.com
Shayne Gilliatt of Generex Biotechnology Corporation, 1-800-391-6755, or
+1-416-364-2551; or Ken Sgro of CEOcast, Inc., 212-732-4300,
kensgro@ceocast.com, for Generex Biotechnology Corporation
» return to top
|
